ABOS News and Press, Acumen Pharmaceuticals Inc. From 10/27/23

- Acumen presented data exploring target engagement modeling of ACU193, the first clinical-stage amyloid beta oligomer (AβO)-targeting antibody, to inform dose selection, plus further analyses of dose-related amyloid plaque reduction and clinical characteristics of ARIA-E, confirming proof...

2023-10-18 17:39:01 ET Gainers: Netflix ( NFLX ) +12% . Melco Resorts & Entertainment  ( MLCO ) +5% . ADTRAN Holdings ( ADTN ) +4% . Acumen Pharmaceuticals ( ABOS ) +4% . Gracell Biotechnologies  ( GRCL ) +4% . ...

Expanded analyses from robust Phase 1 INTERCEPT-AD trial exploring novel target engagement (dose-related), amyloid plaque reduction, and ARIA levels observed with ACU193 administration to be included in a symposium on Friday, October 27 New data from additional exploratory analyses of...

2023-10-03 11:03:22 ET Summary Acumen Pharmaceuticals' ACU193 shows promise as a potential treatment for early-stage Alzheimer's Disease, targeting amyloid beta oligomers with a more favorable safety profile. Q2 earnings show increased operating expenses and a net loss expansion, ...

2023-10-03 05:15:10 ET Summary Acumen Pharmaceuticals is developing a monoclonal antibody, ACU193, that targets Amyloid beta oligomers (AβOs) in Alzheimer's disease. AβOs are small, soluble aggregates of amyloid-beta peptides that are believed to be more toxic to neu...

CHARLOTTESVILLE, Va. and CARMEL, Ind., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer’s disease, a...

CHARLOTTESVILLE, Va. and CARMEL, Ind., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer’s disease, a...

2023-08-11 09:52:01 ET Acumen Pharmaceuticals, Inc. (ABOS) Q2 2023 Earnings Conference Call August 08, 2023 08:00 AM ET Company Participants Alex Braun - Head-Investor Relations Dan O'Connell - Chief Executive Officer Eric Siemers - Chief Medical Officer Matt...

2023-08-08 07:43:40 ET Acumen Pharmaceuticals press release ( NASDAQ: ABOS ): Q2 GAAP EPS of -$0.28 beats by $0.07 . As of June 30, 2023, cash, cash equivalents and marketable securities totaled $172.2 million, compared to cash, cash equivalents and marketable securiti...

Positive INTERCEPT-AD Phase 1 trial results announced in July 2023 demonstrate ACU193’s potential as a differentiated antibody for the treatment of early Alzheimer’s disease Cash, cash equivalents and marketable securities of $172.2 million as of June 30, 2023, bolstered by ...